Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Phase 2 data: Inotuzumab, approved in adults with B-ALL, shows promise in kids, too

Publish date:: February 11, 2020

Key clinical point: Inotuzumab ozogamicin shows promising safety and efficacy in children and young adults with R/R B-ALL.

Major finding: The overall CR/CRi rate after 1 cycle of treatment was 58.3%.

Study details: A phase 2 study of 48 patients.

Disclosures: COG AALL1621 was funded by NCTN grants, St. Baldrick’s Foundation, and Pfizer. Dr. O’Brien reported research funding from Pfizer, Celgene, AbbVie, Amgen, Bristol-Myers Squibb, and BTG.

Citation:

O’Brien M et al. ASH 2019, Abstract 741.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,